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Abstract 
Sensorineural hearing losses (SNHLs; e.g., ototoxicant- and noise-induced hearing loss or 
presbycusis) are among the most frequent sensory deficits, but they lack effective drug therapies. 
The majority of recent therapeutic approaches focused on the trials of antioxidants and reactive 
oxygen species (ROS) scavengers in SNHLs. The rationale for these studies was the prominent 
role of disturbed redox homeostasis and the consequent ROS elevation. Although the antioxidant 
therapies in several animal studies seemed to be promising, clinical trials have failed to fulfil 
expectations. 
We investigated the potential of rasagiline, an FDA-approved MAO-B inhibitor type 
antiparkinsonian drug, as an otoprotectant. We showed a dose-dependent alleviation of the 
kanamycin-induced threshold shifts measured by auditory brainstem response (ABR) in an 
ototoxicant aminoglycoside antibiotic-based hearing loss model in mice. This effect proved to be 
statistically significant at a 6 mg/kg (s.c.) dose. The most prominent effect appeared at 16 kHz, 
which is the hearing sensitivity optimum for mice. The neuroprotective, antiapoptotic and 
antioxidant effects of rasagiline in animal models, all targeting a specific mechanism of 
aminoglycoside injury, may explain this otoprotection.  
The dopaminergic neurotransmission enhancer effect of rasagiline might also contribute to the 
protection. Dopamine (DA), released from lateral olivocochlear (LOC) fibres, was shown to exert 
a protective action against excitotoxicity, a pathological factor in the aminoglycoside-induced 
SNHL. We have shown that rasagiline enhanced the electric stimulation-evoked release of DA 
from an acute mouse cochlea preparation in a dose-dependent manner. Using inhibitors of 
voltage-gated Na+-, Ca2+ channels and DA transporters, we revealed that rasagiline potentiated 
the action potential evoked-release of DA by inhibiting the reuptake. 
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The complex, multifactorial pathomechanism of SNHLs most likely requires drugs acting on 
multiple targets for effective therapy. Rasagiline, with its multi-target action and favourable 
adverse effects profile, might be a good candidate for a clinical trial testing the otoprotective 
indication. 
 
 
Keywords: sensorineural hearing loss; kanamycin; auditory brainstem response; lateral 
olivocochlear efferents; dopamine; rasagiline 
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Introduction 
 
SNHLs and the lack of their effective pharmacological treatment 
Hearing loss (HL) is the most frequent human sensory deficit. In contrast to its conductive forms, 
there is no specific drug therapy for sensorineural hearing losses (SNHLs; e.g., ototoxicant drug- 
and noise-induced HL or presbycusis), except for symptomatic approaches with moderate 
efficacy. One of the main reasons for the absence of specific tools to prevent and cure SNHLs is 
the insufficient knowledge of the basic molecular mechanisms of normal and impaired adult 
hearing and of the endogenous protective factors.  
A consensus is evolving that the imbalance of the redox homeostasis and the consequent increase 
in reactive oxygen and nitrogen species (ROS, RNS) is a common pathological basis in all the 
acquired forms of SNHLs (Mukherjea et al., 2011), as well as in the many inherited forms 
(Noben-Trauth and Johnson, 2009). This knowledge initiated testing of different antioxidants and 
ROS scavengers (Tabuchi et al., 2010; Mukherjea et al., 2011) for the protection of the cells of 
the organ of Corti and auditory neurons, which are primary targets in SNHLs.  
 
Rasagiline  
Rasagiline, a selective propargylamine inhibitor of monoamine oxidase inhibitor (MAO) type B, 
has been applied to Parkinson’s Disease in clinical practice (Finberg, 2010). In addition to 
selectively inhibiting the dopamine (DA) metabolising enzyme MAO-B, it also has a cell 
protective action. It has been shown to protect against neural degeneration (Huang et al., 1999; 
Speiser et al., 1999; Youdim et al., 2006), oxidative damage and apoptosis (Tabakman et al., 
2004; Siderowf and Stern, 2006). These protective effects provide a rational to test its effect in 
different forms of SNHLs. Furthermore, as an enhancer of DAergic neurotransmission (Weinreb 
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et al., 2010) in the central nervous system, it may also potentiate the release of DA from the 
lateral olivocochlear (LOC) efferents, which is considered to be a protective feedback pathway of 
the cochlea (Pujol et al., 1993; Pujol, 1994; Lendvai et al., 2011; Maison et al., 2013). 
 
The cochleoprotective role of DA released from LOC efferent fibres  
It has been shown that the excessive release of glutamate (Glu) from inner hair cells (IHCs) in 
noise-induced HL, presbycusis, cochlear ischemia or aminoglycoside-induced ototoxicity results 
in the excitotoxic damage of the primary auditory neurons (Duan et al., 2000; Ruel et al., 2007; 
Tabuchi et al., 2010; Bernarding et al., 2013). LOC efferents, forming axodendritic synapses with 
the auditory neurons, serve as the effector arm of the auditory neurons – cochlear nucleus – 
lateral superior olivary complex – cochlea short-loop feedback and provide protection to the 
auditory neurons against excitotoxicity by releasing DA. DA inhibits the postsynaptic effects of 
Glu and protects the IHC-afferent nerve synapse (Halmos et al., 2005, 2008; Ruel et al., 2007; 
Lendvai et al., 2011). Intracochlear application of the D2/D3 dopamine receptor agonist piribedil 
reduced the characteristic electrophysiological and structural changes evoked by acoustic trauma 
and ischemia (Pujol et al., 1993; d’Aldin et al., 1995a, 1995b; Gil-Loyzaga, 1995), and D1, D2 
receptor agonists were shown to inhibit the NMDA- and AMPA-induced firing of the primary 
afferent nerve (Oestreicher et al., 1997). Although drugs acting on the DAergic system have not 
yet been tested thoroughly, theoretically, any drug able to boost the function of this system could 
hold preventive or curative promises for SNHLs (Halmos et al., 2005; Lendvai et al., 2011). 
 
Aminoglycoside ototoxicity and its use as a SNHL model 
Aminoglycoside antibiotics, which still need to be used in the treatment of certain serious 
infections caused by aerobic gram-negative bacteria, can induce irreversible HL (Xie et al., 
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2011). Hair cells, especially the outer hair cells and the IHC ribbon synapse, together with the 
auditory neurons, are very vulnerable to the administration of aminoglycosides (Ylikoski et al., 
1974; Dodson, 1997; Duan et al., 2000; Maruyama et al., 2008; Fransson et al., 2010; Liu et al., 
2013). The pivotal role of normal redox state disturbances, generation of ROS and excitotoxic 
damage of the auditory neurons in the pathomechanism has been shown in several studies (Basile 
et al., 1996; Sha and Schacht, 1999; Duan et al., 2000; Poirrier et al., 2010; Huth et al., 2011). 
This serious side effect is the basis of a well-established animal model used in hearing research 
(Wu et al., 2001). As the aminoglycoside induced HL involves oxidative stress, ROS generation 
and excitotoxic neuronal damage, we tested the effect of rasagiline in the kanamycin-induced 
hearing loss model. 
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Experimental Procedures 
 
In vivo measurement of the rasagiline effect in the aminoglycoside-induced ototoxicity model 
General experimental paradigm of kanamycin-induced ototoxicity and application of rasagiline. 
All animal care and experimental procedures were in accordance with the National Institute of 
Health Guide for the Care and Use of Laboratory Animals. Procedures were approved by the 
Animal Use Committee of the Institute of Experimental Medicine, Hungarian Academy of 
Sciences. Selections of the mouse strain and the type and concentration of aminoglycoside 
antibiotic were based on data from the literature (Wu et al., 2001). Our preliminary experiments 
(data not shown) testing different mouse strains, aminoglycoside antibiotics and concentrations of 
kanamycin, confirmed that the most pronounced and reliable aminoglycoside-induced hearing 
loss, suitable for testing otoprotection, could be produced in BALB/c mice by administering 
kanamycin in an 800 mg/kg subcutaneous (s.c.) dose. Male BALB/c mice, age 4 weeks, were 
purchased from Charles River, Germany. 
First, a set of experiments exploring also the dynamics of the effect of kanamycin and rasagiline 
was carried out. Mice were assigned to one of the following four experimental groups: 1. Control 
(physiological saline), 2. Kanamycin, 800 mg/kg, 3. Rasagiline, 3 mg/kg, and 4. Kanamycin, 800 
mg/kg + Rasagiline, 3 mg/kg. Treatment groups contained 8 mice each. (One mouse in group 4 
died during the auditory brainstem response (ABR) measurement under anaesthesia.) Kanamycin 
sulphate (USB Corporation, Cleveland, OH) was injected s.c. twice daily (8-9 a.m. and 6-7 p.m.) 
for 2 weeks. The first dose of the antibiotic was administered on the day of the first ABR 
measurement (6-7 p.m.) after all the measurements had been performed. Doses of rasagiline 
mesylate (3 mg/kg, s.c.; TEVA) were given once daily at the same time as the morning dose of 
kanamycin, but the injections were separate. In this way, the first dose of rasagiline was delivered 
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14 h after the first kanamycin dose. Rasagiline treatments lasted 5 weeks. Mice in the Control 
group were injected s.c. by an equivalent amount of physiological saline. In the kanamycin 
treatment group, after the 2nd week, the kanamycin injections were replaced by injections of 
physiological saline till the end of the 5th week. 
Auditory thresholds were determined in both ears from the ABRs. Thresholds were taken from 
each animal prior to the start of the drug treatments on the 1st week (start-up threshold), 2 weeks 
after the start of drug treatment, and then weekly up to 5 weeks (5 measurements in sum). The 
threshold shift gives the difference of an actual threshold value and the threshold measured in the 
same mouse before any treatment (start-up threshold). 
Based on the time-dependent threshold changes measured in the first set of experiments, a 3-
week-long experiment was performed, and two other doses of rasagiline were tested (1. Control, 
2. Kanamycin, 800 mg/kg, 3. Kanamycin, 800 mg/kg + Rasagiline, 0.5 mg/kg, 4. Kanamycin, 
800 mg/kg + Rasagiline, 6 mg/kg). The ABR was measured in the left ear exclusively. The 
experiment was carried out with larger sample sizes (n=20 in each treatment group), which were 
calculated based on the first set of experiments. Two mice in the Control group, one in the 
Kanamycin group and two in the Kanamycin + Rasagiline, 6 mg/kg treatment group died during 
the ABR measurement under anaesthesia. The kanamycin dose and the treatment protocols were 
the same as before.  
 
In vivo recordings of auditory brainstem responses (ABRs). Mice were anaesthetised by 
intraperitoneal (i.p.) injections of ketamine (100 mg/kg) and xylazine (10 mg/kg). Body 
temperature was maintained by a feedback-controlled heating pad. The auditory thresholds were 
determined by an ABR workstation (Tucker-Davis Technologies, Alachua, FL). Click (0.4 ms 
duration) and tone burst (3 ms duration, 0.2 ms rise/decay) stimuli were generated by the SigGen 
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software package and delivered in a closed acoustic system to the external auditory meatus 
through a plastic tube connected to an EC1 electrostatic speaker. ABRs were recorded with 
subdermal needle electrodes as the potential difference between an electrode on the vertex and an 
electrode behind the left or right pinna. The rear leg served as a ground. The evoked responses 
were amplified, and 800 sweeps were averaged in real time. The intensity was increased in 10 dB 
steps from 0 to 80 dB in click stimulation mode. To obtain auditory thresholds at different 
frequencies, the sound intensity of the tone burst stimuli were attenuated in 10 dB steps. 
Threshold was defined as the lowest intensity at which a visible ABR wave was seen.  
 
Statistical analysis. Threshold data in both studies were analysed using a linear mixed statistical 
model (to take into account the fact that every animal was measured on each frequency, the 
“nlme” package of the R statistical program was used (Jose Pinheiro, Douglas Bates, Saikat 
DebRoy, 2013; R Core Team, 2013), followed by pairwise comparisons of the treatments, 
calculated using contrasts (Warnes, 2011). Left and right ear values were averaged in the first set 
of experiments. Model effects were tested together based on their F values. All factors and 
potential interactions were evaluated with the cut-off for inclusion of P <0.05. The Tukey-
Kramer corrections of p-values and confidence limits were applied.  
 
In vitro measurement of DA release from the LOC terminals 
Measuring the release of DA from mouse and guinea-pig cochlea. CD-1 male mice, weighing 20-
35 g, were used. Procedures were approved by the Animal Use Committee of the Institute of 
Experimental Medicine, Hungarian Academy of Sciences. We used the microvolume superfusion 
method as described earlier (Gáborján et al., 1999; Halmos et al., 2005, 2008). Briefly, the bulla 
tympani was opened. The bony capsule of the cochlea was removed under stereomicroscopic 
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guidance, the stria vascularis was stripped, and the cochlea was fractured at the basis of the 
modiolus. Our preparation contained the ganglion spirale, the afferent auditory fibres, the axons 
and axon terminals of the efferent bundles and both the inner and outer hair cells. All experiments 
were carried out in a perilymph-like solution (Ikeda et al., 1991), which contained 150 mM NaCl, 
3.5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 2.75 mM HEPES and 2.25 mM Tris at 37°C. The pH 
was adjusted to 7.4. The osmolarity was set by D-glucose, and the solution was gassed 
continuously with 100 % O2. 
The cochleae were incubated with 0.2 µM [3H]dopamine (specific activity: 31.0 - 59.3 Ci/mmol; 
[7,8-3H]DA, Amersham, UK) for 35 min, placed in a microvolume plexi chamber (three cochleae 
per chamber) and then superfused with a perilymph-like solution (3 ml/min). After one hour pre-
perfusion, the outflow was collected in 3 min fractions. The released radioactivity, indicating the 
release of DA from the LOC terminals, was determined by assaying 500 µl aliquots of each 
sample with a liquid scintillation counter (Packard Tri-Carb 1900TR). After collecting the 
samples for 57 minutes (19 fractions), each cochlea was transferred from the microchambers to 
500 µl of 10 % trichloroacetic acid for one day; 100 µl was then used to measure the tissue 
content of the radioactivity. Earlier HPLC measurements in our laboratory showed that 91-95 % 
of the released radioactivity was attributable to [3H]DA and its metabolites DOPAC and HVA 
(Gáborján and Vizi, 1999). 
Electrical field stimulation, evoking action potentials in the LOC efferents, was applied for one 
collection period (3 min) at 30 V, 5 Hz and 0.5 ms impulse duration at the 3rd (S1) and 13th (S2) 
fractions. The pulses were delivered by a Grass S88 stimulator (West Warwick, USA) through 
platinum electrodes at the top and bottom of the tissue chamber. Rasagiline was added to the 
perfusion solution at the beginning of the 8th fraction (21th min) and was maintained till the end of 
the experiment. Perfusion of CdCl2 and TTX was started 6 min earlier (from the 15th min). The 
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application of nomifensine and a decrease in the temperature to 17 °C were started in the 45th min 
of pre-perfusion and were maintained till the end of the experiment. 
In addition to the reversibility and reproducibility of DA release and its inhibition by voltage-
gated sodium (VGSC) or voltage-gated calcium channel (VGCC) blockade (indications of 
neuronal exocytosis; see Gáborján & Vizi 1999; Gáborján et al. 1999; Halmos et al. 2008), the 
viability of the cochlear preparation was also shown by light- and electron microscopy (EM) 
performed immediately before and after the experiments (Halmos et al., 2008).  
 
Data analysis and statistics. To best describe the release of DA during one collecting period, the 
fractional release (FR) of the tritium outflow was determined as the percentage of the total 
radioactivity present in the tissue at the time of sample collection. The FR due to the field 
stimulations (S1 and S2) was calculated by the area-under-the-curve, i.e., by subtracting the mean 
of the basal release, determined from FR values before and after the stimulation, from the total 
FR during the electrical stimulation (Halmos et al., 2000, 2005). The effects of drugs on the field 
stimulation-evoked [3H]DA release were expressed by the calculated ratio of FR S2 over FR S1 
(FRS2/FRS1). Data are expressed as the means ± S.E.M. Analysis of variance (ANOVA) 
followed by Tukey’s Honest Significant Difference method for multiple comparisons was used to 
compare the treatment groups with the R 14.1 program. Levels of significance were as follows: 
*p<0.05, **p<0.01 and ***p<0.001. 
  
 
 12
Results 
 
In vivo effect of rasagiline on aminoglycoside-induced hearing impairment. The effect of 
rasagiline on SNHL was tested in the kanamycin-induced hearing loss model in mice (Wu et al., 
2001). Auditory thresholds were measured at four different frequencies. 
First, a five-week-long study was started with 8 mice in each treatment group (Fig. 1) to explore 
the time dependency of the threshold changes. Kanamycin (800 mg/kg, s.c.), administered for 
two weeks twice daily impaired the hearing of BALB/c mice. The shift of the auditory thresholds 
was highly significant (p < 0.001) at higher frequencies (16 and 24 kHz), while the ototoxic 
effect was less pronounced at lower frequencies (not even significant at 8 kHz, see the legend of 
Fig. 1). After 3 weeks, a plateau in impairment was reached (Fig. 1). Administration of rasagiline 
showed a clear tendency of attenuation of the kanamycin-induced threshold elevation. This is 
clearly seen at all four frequencies at any time point measured, although the difference was not 
statistically significant (Fig. 1). Contrary, the trace of rasagiline administration alone (3 mg/kg) 
was sometimes below, sometimes above the control trace (physiological saline) at all four 
frequencies during the 5-week-long experiment. This is in accordance with the lack of significant 
effect of rasagiline on the ‘control’ threshold (Fig. 1). 
The kanamycin-induced hearing loss developed thoroughly up to the 3rd week, and the influence 
of rasagiline on kanamycin action did not change during the five weeks. Therefore, in a second 
set of experiments, we tested the effect of rasagiline on threshold shifts in the 3rd week at 0.5 and 
6 mg/kg (s.c.) doses. Administration of kanamycin caused a significant shift in the auditory 
thresholds both in click (p < 0.01) and tone burst stimulation modes (4 kHz, p < 0.05; 8 kHz, p < 
0.001; 16 kHz, p < 0.001; 24 kHz, p < 0.001). The effect was more robust at the higher 
frequencies (Fig. 2). Rasagiline mitigated the kanamycin-evoked hearing impairment by 0.5 – 8 
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and 8 – 19 dB when applied in 0.5 and 6 mg/kg dose, respectively. The dose-dependency of the 
rasagiline effect was more prominent when its action in 3 mg/kg dose was included in the 
plotting (Fig. 2). The most pronounced protection appeared at 16 kHz (Fig. 2). 
We showed in a separate experiment that rasagiline alone did not influence significantly the 
auditory thresholds during the 3-week-long treatment even in the highest dose (6 mg/kg). The 
estimated overall difference was 0.24 ± 0.928 dB (p = 0.798, n = 7). 
 
Effect and mode of action of rasagiline on the release of DA from mouse cochlea 
Rasagiline enhanced the electrical field stimulation-evoked release of DA from isolated mouse 
cochlea preparations (Fig. 3). The effect was concentration-dependent and reached a plateau at 
100 µM (Fig. 3, inset). The resting release of DA was not affected in any concentration applied 
(Fig. 3). 
To explore the possible molecular mechanism of the action underlying the effect of rasagiline on 
the DA release evoked by the field stimulation, we tested the effect of 100 µM rasagiline during 
the inhibition of VGCCs and VGSCs. In the presence of Cd2+ (100 µM) and TTX (1 µM), 
respectively, the stimulation-evoked release was completely inhibited, providing evidence that 
the release of DA was due to axonal activity and Ca2+ influx. Under these conditions, rasagiline 
failed to increase the release of DA (Fig. 4). 
Blocking the reuptake of DA into the nerve terminals is a known way of potentiation of DAergic 
neurotransmission. In order to test whether the uptake inhibition is a possible mechanism in 
rasagiline action on cochlear DA release, we measured the effect of rasagiline in the presence of 
uptake inhibition by low temperature or nomifensine. Cooling down the temperature to 17 °C 
before S2, but after S1, approximately doubled the FRS2/FRS1 ratio (2.52 ± 0.4, n = 4), 
confirming its efficacy in inhibition of the uptake, similar to what we have shown in brain slices 
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(Vizi, 1998; Vizi et al., 2004). The inhibitory effect of 10 µM nomifensine on mouse cochlear 
DA reuptake has already been demonstrated in our previous work (Halmos et al., 2008). During 
inhibition of DA uptake by either nomifensine (10 µM) or low temperature (17 °C), the 
potentiating effect of rasagiline was hampered significantly. These findings indicate that 
rasagiline inhibits DA uptake in isolated in vitro cochlea preparations, thereby potentiating DA’s 
release from the LOC in response to axonal activity (Fig. 5). 
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Discussion 
 
Current therapeutic regimen and potential new drugs in SNHLs 
Contrary to the conductive HLs, there are no specific pharmaceuticals for the sensorineural forms 
in the treatment of hearing deficits. Various hearing aids and cochlear implants have been proven 
to be effective therapies in appropriate clinical cases; however, a specific drug therapy is still 
missing. In current clinical practice, steroids, thrombolytics, vasodilators and nootropic drugs are 
administered.  
Potentially new therapeutic approaches in SNHLs based on animal studies, including antioxidants 
and ROS/RNS scavengers, apoptosis inhibitors, neuroprotective compounds, anti-inflammatory 
drugs (such as steroids, aspirin or TNF-α inhibitors), neurotrophic factors or different gene 
therapeutic approaches (Atar and Avraham, 2005; Rybak and Whitworth, 2005; Maruyama et al., 
2008; Fransson et al., 2010; Mukherjea et al., 2011; Rudnicki and Avraham, 2012; Kohrman and 
Raphael, 2013), have been applied, but they have failed to fulfil expectations. Although several 
animal studies have shown significant effects of antioxidant therapy, clinical studies have not yet 
reached a conclusive result (Tabuchi et al., 2010; Mukherjea et al., 2011). Therefore, we 
considered it relevant to test whether rasagiline, a registered drug with a complex 
neuroprotective, antiapoptotic and antioxidant effect, possessed any otoprotective action. 
 
Testing the potential otoprotective action of rasagiline in vivo in an aminoglycoside-induced 
form of SNHL 
Compounds showing a potential to prevent or cure hearing impairments in in vitro experiments 
need reliable in vivo testing to support their applicability in therapy. The otoprotective effects of a 
compound can be tested in vivo by measuring its effect on an auditory threshold elevated by a 
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pathological insult. The use of aminoglycoside antibiotics, which have a well-known ototoxic 
side effect in medical practice, is widely accepted for evoking hearing impairment and testing 
potentially otoprotective compounds (Basile et al., 1996; Song et al., 1997; Duan et al., 2000; 
Nekrassov and Sitges, 2000; Wu et al., 2001). The mechanism of aminoglycosides-induced 
toxicity involves excitotoxicity (Basile et al., 1996; Duan et al., 2000) and the pivotal role of 
oxidative stress and ROS (Basile et al., 1996; Sha and Schacht, 1999; Poirrier et al., 2010; Huth 
et al., 2011). To determine the threshold in vivo, the recording of the ABR is a method of choice 
to obtain objective audiograms. The mouse is a well-established experimental model for human 
audition as it possesses a similar cochlear anatomy, physiology and pattern of ototoxicity-related 
hearing loss (Wu et al., 2001; Fernandez et al., 2010). 
Based on the literature (Wu et al., 2001) and preliminary experiments, we used 800 mg/kg 
kanamycin (s.c.) for two weeks in our aminoglycoside-induced SNHL model to test the 
otoprotective potential of rasagiline in vivo. The kanamycin-evoked shift in the auditory 
thresholds was more pronounced at higher frequencies, which was in perfect accordance with the 
observations of other studies in both human clinical practice and in laboratory animals. 
Aminoglycoside ototoxicity appears as a high frequency SNHL. (Wu et al., 2001; Guthrie, 2008). 
Plotting the auditory thresholds as a function of time, measured at different frequencies, 
demonstrated that the plateau in the effect of kanamycin was reached after 3 weeks. This result 
was in good agreement with prior clinical observations that the ototoxic effect of the 
aminoglycosides might start after the cessation of treatment, develop slowly and ultimately 
become irreversible (Xie et al., 2011). In our experiments, the kanamycin-induced hearing loss 
had a tendency to be attenuated by the concomitant application of a single dose per day of 
rasagiline (3 mg/kg), and this beneficial tendency was maintained at multiple frequencies during 
the experiments that lasted for five weeks. The effect of rasagiline on the auditory thresholds 
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showed dose-dependency. The most pronounced effect was exerted at 16 kHz. This frequency is 
right in the range of the hearing sensitivity optimum (15-20 kHz) of the mouse (Ehret, 1976) and 
is the equivalent of the human 1-4 kHz optimum. With these findings, it is tempting to 
hypothesise that the otoprotection by rasagiline could be predominantly exerted in the frequency 
range most relevant to speech acquisition. 
The question arises regarding the potential mechanism of the otoprotective action of rasagiline. 
Rasagiline, indicated for the treatment of idiopathic Parkinson's disease by the FDA, possesses 
neuroprotective, anti-apoptotic and antioxidant properties all in one. It upregulates the synthesis 
of anti-apoptotic members of the Bcl-2 family and of the neurotrophic factors BDNF and GDNF, 
while it downregulates the pro-apoptotic Bad and Bax proteins (Bar-Am et al., 2005; Weinreb et 
al., 2005; Youdim et al., 2006). It also increases antioxidant enzyme (glutathione peroxidase and 
catalase) activities (Kitani et al., 2000) and inhibits mPTP opening, mitochondrial swelling and 
cytochrome c release (Youdim et al., n.d.; Maruyama et al., 2001; Akao et al., 2002) and caspase 
3 activation (Bar-Am et al., 2005). A decrease in the synaptic density of NMDA- and AMPA 
receptors, responsible for initiating excitotoxicity , has also been reported with rasagiline 
treatment (Gardoni et al., 2011). These cellular mechanisms are considered responsible for the 
positive in vivo effects of rasagiline. In addition, rasagiline has provided protection in closed head 
injury (Huang et al., 1999) and in experimental focal ischemia (Speiser et al., 1999), and it was 
also supposed to slow the progression of Parkinson’s disease (Hoy and Keating, 2012). 
Furthermore, its neuroprotective effect has also been demonstrated in the peripheral nervous 
system, i.e., in the retina (Eigeldinger-Berthou et al., 2012). 
These effects of rasagiline may counteract the damages that aminoglycosides cause by disturbing 
redox homeostasis, producing ROS (Basile et al., 1996; Sha and Schacht, 1999; Poirrier et al., 
2010; Huth et al., 2011), and by impairing the function of auditory neurons via excitotoxicity 
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(Ruel et al., 2007; Tabuchi et al., 2010) and depletion of the essential neurotrophic factors 
(Poirrier et al., 2010). 
In addition to these well characterised actions, rasagiline also potentiates DAergic 
neurotransmission in the brain (Weinreb et al., 2010), and DA has an important role in the 
feedback loop providing endogenous protection against SNHLs (Lendvai et al., 2011). Moreover, 
a recent study based on screening a library of FDA-approved pharmaceuticals consisting of 640 
compounds found that DA-modulating drugs bear protective effects against ototoxic 
aminoglycosides and cisplatin (Vlasits et al., 2012). 
 
Endogenous protective pathway in the cochlea – boosting effect of rasagiline on LOC terminals 
to increase DA release  
In our in vitro experiments, we investigated the potential of rasagiline to enhance the release of 
DA from the LOC terminals. DA-containing LOC fibres compose the efferent part of the 
cochlea-brainstem short-loop feedback, which plays an important role in inhibiting the harmful 
overactivation of the auditory neurons (Pujol, 1994; Ruel et al., 2007; Lendvai et al., 2011). The 
overactivation of the Glu receptors is the consequence of the excessive release of Glu from hair 
cells, occurring in different types of SNHLs (Lendvai et al., 2011), and this excitotoxicity leads 
to neuronal damage, like in ischemic brain injury (Vizi et al., 2013). Considering the protective 
actions of cochlear DA, several target sites have appeared as candidates for increasing the 
endogenous DAergic protection. We have already shown that 5-HT6/7 antagonists (Doleviczényi 
et al., 2008), group II mGluR ligands (Doleviczényi et al., 2005), selective NMDA receptor 
agonists (Halmos et al., 2008) and D2 DA receptor antagonists (Halmos et al., 2005) provide new 
possibilities for the enhancement of DA release from the LOC terminals in the cochlea (Lendvai 
et al., 2011).  
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Boosting of protective LOC feedback in synchrony with the endogenous, action potential-evoked 
release of DA seems to be superior to simply evoking DA release from the terminal 
independently of the on-going axonal activity of the LOC efferents or to directly activating the 
postsynaptic DA receptors by the administration of appropriate receptor ligands. It can be 
hypothesised that rasagiline, registered as a selective MAO-B inhibitor type antiparkinsonian 
drug, would meet this requirement by inhibiting the metabolism of DA and loading up its stores 
(Hársing and Vizi, 1984) in the LOC terminals. Indeed, rasagiline enhanced the action potential 
evoked release of DA in the cochlea in a dose-dependent manner and did not influence the resting 
release. The relatively higher concentrations needed for its action might be due to the 
predominantly MAO-A dependent deamination of DA in mice (Garrick and Murphy, 1980; 
Fornai et al., 1999). At higher concentration rasagiline loses its MAO-B selectivity and inhibits 
MAO-A, as well (Youdim et al., 2006).   
Properly functioning VGSCs and VGCCs are necessary prerequisites for the classical exocytotic 
release of neurotransmitters. The dependence of the potentiating effect of rasagiline on the proper 
functioning of VGSCs and VGCCs confirmed that its action was connected to the on-going 
axonal activity of the LOC efferents. In contrast to indirect acting sympathomimetics, such as 
amphetamine, which induce the release of DA independently of action-potential-dependent 
vesicular release (Fleckenstein et al., 2007). 
In previous reports inhibition of DA reuptake by rasagiline was found in the central nervous 
system (Lamensdorf et al., 1996; Jankovic and Stacy, 2007). The role of the inhibition of DA 
reuptake into the LOC efferent terminals in the action of rasagiline was supported by the loss of 
the potentiating effect of the drug during the pre-inhibition of DA uptake by the selective DA 
uptake inhibitor nomifensine and by a low temperature. 
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Rasagiline did not enhance the resting release, being in line with the therapeutic aim of boosting 
the action potential based LOC feedback response without causing a continuous and endogenous 
protection independent elevation of DA level. Continuously enhanced level of DA could also be 
resulted in desensitization of DA receptors attenuating the protective effect of the firing LOC 
terminals. 
The question arises regarding how the doses used in vivo relate to the concentrations used in vitro 
and whether the otoprotective concentration of rasagiline could be reached in humans. A 
simplified calculation, presuming 60 % water content of body mass and perfect absorption of 
rasagiline and its distribution in body water suggested that the in vivo doses and the in vitro 
concentrations we used were approximately the same order of magnitude. Considering the 
general experience that the effective human doses are usually lower by an order of magnitude 
than those used in mice and that rasagiline is very well tolerated, its use in SNHLs is a reliable 
possibility. The preferentially MAO-B dependent deamination of DA in human, contrary to the 
mouse, where MAO-A is predominant (Garrick and Murphy, 1980; Fornai et al., 1999), might 
further support the feasibility of a lower dose of the MAO-B inhibitor rasagiline for otoprotection 
in human. 
An otoprotective therapy might be delivered in the form of prevention, intervention or 
regeneration. Theoretically, the preventive therapy holds the highest chance of curative action. In 
our case administration of rasagiline started 14 hours after the first injection of kanamycin and 
still it attenuated the threshold shift significantly in 6 mg/kg dose. 
Direct translation of our results to clinical application would suggest the use of rasagiline in 
prevention or intervention of acute trauma caused by an aminoglycoside antibiotic. However, the 
spectrum of possible therapeutical indications is wider, because of the strong similarities in the 
patomechamism of the different SNHLs (Hawkins, 1973; Poirrier et al., 2010; Mukherjea et al., 
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2011). Oxidative stress and the consequent elevation in ROS level is a key factor in presbycusis 
(Yamasoba et al., 2013), platinum-based anticancer drugs- (Kopke et al., 1997; Schacht et al., 
2012) and noise exposure-induced HLs (Henderson et al., 2006), as well. Degeneration of the 
auditory nerves is also playing an important role in all of these SNHLs (Ylikoski et al., 1974; van 
Ruijven et al., 2005; Makary et al., 2011; Maison et al., 2013; Yamasoba et al., 2013). Therefore 
rasagiline, having antioxidant, neuroprotective and antiapoptotic effect, is predisposed for beeing 
also a promising choice of therapeutic tool for treating SNHLs other than the aminoglycoside 
induced one. In case of antitumor therapy by cisplatin and related compounds the concomitant 
administration of rasagiline to prevent or attenuate the side effects, similarly to its acute use in 
aminoglycoside therapy, might be a feasible way of application. On the other hand, chronic 
treatment with rasagiline seems to be the reasonable therapy in presbycusis and persistent, 
moderate-level noise exposure induced HLs. 
The complex pathomechanism of SNHLs, structured rather like a network than like a linear 
cascade, together with the failure to find the breakthrough in therapy till now, suggests that single 
target interventions hold less promise in the therapy of SNHLs. Based on the significant overlaps 
in the pathomechanism of SNHLs, rasagiline, with its multi-target action, might be effective in 
treating not only the aminoglycoside-induced HL but other forms of SNHLs as well. Its good 
tolerability, proven since its introduction to human therapy in 2006, also supports the 
applicability of this new therapeutic indication. 
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Figure legends 
 
Figure 1. 5-week-long follow-up of in vivo rasagiline effect in an aminoglycoside-induced 
SNHL model in mice. Kanamycin (800 mg/kg, s.c., twice daily) was administered for 2 weeks, 
and it induced an elevation in hearing thresholds, especially at higher frequencies (compared to 
Control; p values were 0.017, 0.066, < 0.001 and < 0.001 at 4, 8, 16 and 24 kHz, respectively). 
Rasagiline treatments (3 mg/kg, s.c., once daily) were started 14 h after the first dose of 
kanamycin, and they lasted 5 weeks. Although rasagiline showed a tendency to decrease the 
kanamycin-induced threshold elevation at all measured time points and frequencies, these effects 
were not statistically significant. Mice in the Control group received physiological saline s.c. 
twice daily for 5 weeks. The effect of rasagiline alone did not differ from the Control. ABRs were 
recorded in BALB/c mice at four frequencies, as described in the Methods. Data are the mean ± 
S.E.M; n = 8, except in Kanamycin + Rasagiline (n = 7). A linear mixed model, followed by 
pairwise comparisons, was used for the statistical analysis (see Methods).  
 
Figure 2. Rasagiline attenuated the kanamycin-induced hearing impairment in BALB/c 
mice. ABRs were recorded right before drug administration (start-up threshold) and 3 weeks later 
as described in the Methods. Threshold shifts were calculated as the difference between the two 
measurements. Kanamycin (800 mg/kg, s.c., twice daily) was administered for 2 weeks, and it 
induced a significant loss of hearing in both the click and frequency selective tone burst 
stimulations. Rasagiline treatments (0.5 and 6 mg/kg, s.c., once daily) were started 14 h after the 
first dose of kanamycin and lasted till the second threshold measurement in the 3rd week. Mice in 
the Control group received physiological saline s.c. Respective data of the Kanamycin + 
Rasagiline, 3 mg/kg treatment (n = 7; no click measurements) were included in the figure (empty 
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bars) to help demonstrate the dose-dependent effect of rasagiline. The inset emphasises this dose-
dependent effect at 16 kHz, which is in the highest sensitivity frequency range of hearing in mice. 
Data are the mean ± S.E.M.; the number of experiments is given in parentheses. A linear mixed 
model, followed by pairwise comparisons, was used for the statistical analysis (see Methods; 
**p<0.01). 
 
Figure 3. Rasagiline increased the electric field stimulation-evoked release of DA in a dose-
dependent manner in the mouse cochlea. Rasagiline was added to the perfusion from the 21st 
min and maintained till the end of the experiment (horizontal line). S1 and S2 bars show the 
electrical field stimulations (5 Hz, 0.5 ms, 900 shocks). Rasagiline was applied in the 10-300 µM 
concentration range (Ras 10, Ras 30, Ras 100 and Ras 300). The inset indicates the dose-
dependent rasagiline effect on the electrical stimulation-evoked fractional release (FR) of DA, 
which is expressed as the FRS2/FRS1 value (ratio of the effect of stimulation in the presence 
compared to the absence of rasagiline). Data presented are means ± SEM; the number of 
experiments is given in parentheses. 
 
Figure 4. Rasagiline (100 µM) did not have any effect on electrical field stimulation-evoked 
DA release during inhibition of VGCCs or VGSCs. A) Blocking VGCCs (Cd2+, 100 µM) and 
VGSCs (TTX, 1 µM) hindered the effect of electric stimulation on the fractional release (FR) of 
DA, and the potentiating effect of rasagiline was also lost. Drug application is indicated by the 
respective horizontal lines. B) Summary and statistical analysis of the effect of Cd2+ (100 µM), 
TTX (1 µM), rasagiline (100 µM; Ras 100) and their combined application on electrical field 
stimulation-evoked DA release (FRS2/FRS1). The asterisks indicate that all treatment resulted in 
a significant effect compared to the Control. Rasagiline lost its potentiating effect in the presence 
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of VGCC and VGSC inhibition (n.s., not significant). Data are presented as means ± S.E.M. The 
number of experiments was 6-6 in each treatment groups, except for in the Control (n = 20). 
ANOVA followed by Tukey’s multiple comparisons; ***p<0.001. 
 
Figure 5. Inhibition of DA uptake carriers by nomifensine or low temperature inhibited the 
rasagiline-induced potentiation of the electrical field stimulation-evoked DA release in the 
mouse cochlea. Application of nomifensine (10 µM) or cooling down the perfusion buffer to 17 
°C was started 15 min before the beginning of the measurement of DA release (i.e., in the pre-
perfusion) and was maintained till the end of the experiment. Rasagiline was administered before 
S2, as in all the other experiments. Asterisks show the comparisons to Nomif 10 and 17 °C, 
respectively. Further comparisons are indicated with the hashmarks. Data are presented as means 
± SEM; n = 6 in all treatment groups. ANOVA followed by Tukey’s multiple comparisons; 
*p<0.05, **p<0.01, ***p<0.001. Nomif 10, nomifensine, 10 µM; Ras 30, rasagiline, 30 µM; Ras 
100, rasagiline, 100 µM. 
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• Rasagiline protected against the kanamycin-induced hearing loss, a form of SNHLs, in 
mice. 
• Rasagiline enhanced the action potential-evoked release of DA from LOC efferents in the 
cochlea. 
• DA releasing effect of rasagiline was dose-dependent and involved the inhibition of the 
reuptake. 
• The known otoprotection by DA might have contributed to the protective effect of 
rasagiline. 
• Multitarget action of rasagiline may promote its therapeutic potential in SNHLs. 
 
